Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.

被引：2
|
作者：
Mobasher, Mehrdad
Huang, Jane
Elstrom, Rebecca L.
Elhamy, Mostafa
Bernaards, Coen
Hallek, Michael J.
Hillmen, Peter
Kater, Arnon Philip
Kipps, Thomas J.
Seymour, John Francis
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Cologne, D-50931 Cologne, Germany
[3] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps7120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7120
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [22] Phase I Study of ABT-199 (GDC-0199) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed in Diffuse Large B-Cell (DLBCL) and Follicular Lymphoma (FL) at Higher Cohort Doses
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 18 - 19
  • [23] PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES
    Davids, M. S.
    Seymour, J. F.
    Gerecitano, J. F.
    Kahl, B. S.
    Pagel, J. M.
    Wierda, W. G.
    Anderson, M. A.
    Rudersdorf, N. K.
    Gressick, L. A.
    Montalvo, N. P.
    Yang, J.
    Zhu, M.
    Dunbar, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Roberts, A. W.
    HAEMATOLOGICA, 2014, 99 : 525 - 525
  • [24] Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions
    Fischer, Kirsten
    Fink, Anna-Maria
    Bishop, Helen
    Dixon, Mark
    Bahlo, Jasmin
    Chol, Michael Y.
    Weinkove, Robert
    Robinson, Sue
    Dreyling, Martin
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier, Sr.
    Kutsch, Nadine
    Tausch, Eugen
    Ritgen, Matthias
    Humerickhouse, Rod A.
    Humphrey, Kathryn
    Wenger, Michael K.
    Goede, Valentin
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Kipps, Thomas J.
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [25] Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
    Pour, Ludek
    Szarejko, Monika
    Bila, Jelena
    Schjesvold, Fredrik H.
    Spicka, Ivan
    Maisnar, Vladimir
    Jurczyszyn, Artur
    Grudeva-Popova, Zhanet
    Hajek, Roman
    Usenko, Ganna
    Thuresson, Marcas
    Norin, Stefan
    Jarefors, Sara
    Bakker, Nicolaas A.
    Richardson, Paul G.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2024, 109 (03) : 895 - 905
  • [26] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Izumi, Tohru
    Komeno, Takuya
    Terui, Yasuhito
    Chou, Takaaki
    Ikeda, Takashi
    Berg, Deborah
    Fukunaga, Shinichi
    Sugiura, Kenkichi
    Sasaki, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
  • [27] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Tohru Izumi
    Takuya Komeno
    Yasuhito Terui
    Takaaki Chou
    Takashi Ikeda
    Deborah Berg
    Shinichi Fukunaga
    Kenkichi Sugiura
    Makoto Sasaki
    International Journal of Clinical Oncology, 2022, 27 : 224 - 233
  • [28] A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Attal, M.
    San Miguel, J.
    Campana, F.
    Le-Guennec, S.
    Hui, A. -M.
    Risse, M. -L.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 779 - 779
  • [29] Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Rudersdorf, Nikita
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Jianning
    Zhu, Ming
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
    Geng, Chuanying
    Hou, Jian
    Zhao, Yaozhong
    Ke, Xiaoyan
    Wang, Zhao
    Qiu, Lugui
    Xi, Hao
    Wang, Fuxu
    Wei, Na
    Liu, Yan
    Yang, Shifang
    Wei, Peng
    Zheng, Xiangjun
    Huang, Zhongxia
    Zhu, Bing
    Chen, Wen-Ming
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (11) : 1037 - 1042
12345